World Library  
Flag as Inappropriate
Email this Article

Cd30

Article Id: WHEBN0002980407
Reproduction Date:

Title: Cd30  
Author: World Heritage Encyclopedia
Language: English
Subject: Primary effusion lymphoma, Hodgkin's lymphoma, Lymphocytic leukemia, Diffuse infiltrative lymphocytosis syndrome, Primary mediastinal B-cell lymphoma
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Cd30

Tumor necrosis factor receptor superfamily, member 8
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols  ; CD30; D1S166E; Ki-1
External IDs GeneCards:
RNA expression pattern
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker.

Contents

  • Function 1
  • Clinical significance 2
  • Cancer treatment 3
  • Interactions 4
  • References 5
  • Further reading 6
  • External links 7

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[1]

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.[2] CD30 and CD15 are also expressed on classical Hodgkin Lymphoma Reed-Sternberg cells.[3]

Cancer treatment

CD30 is the target of the FDA approved therapeutic Brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. It is approved for use in:

  1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
  2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
  3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen[4]

Interactions

CD30 has been shown to interact with TRAF5,[5] TRAF1,[6] TRAF2[5][6] and TRAF3.[6]

References

  1. ^ "Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8". 
  2. ^ Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL (Nov 2005). "[Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors]". Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology (in Chinese) 34 (11): 711–5.  
  3. ^ Gorczyca W, Tsang P, Liu Z, Wu CD, Dong HY, Goldstein M, Cohen P, Gangi M, Weisberger J (Feb 2003). "CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis". International Journal of Oncology 22 (2): 319–24.  
  4. ^ Deng C, Pan B, O'Connor OA (Jan 2013). "Brentuximab vedotin". Clinical Cancer Research 19 (1): 22–7.  
  5. ^ a b Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry 272 (4): 2042–5.  
  6. ^ a b c Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss HJ (Nov 1996). "Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation". Proceedings of the National Academy of Sciences of the United States of America 93 (24): 14053–8.  

Further reading

  • Schneider C, Hübinger G (Jul 2002). "Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family". Leukemia & Lymphoma 43 (7): 1355–66.  
  • Horie R, Higashihara M, Watanabe T (Jan 2003). "Hodgkin's lymphoma and CD30 signal transduction". International Journal of Hematology 77 (1): 37–47.  
  • Tarkowski M (Jul 2003). "Expression and a role of CD30 in regulation of T-cell activity". Current Opinion in Hematology 10 (4): 267–71.  
  • Granados S, Hwang ST (Jun 2004). "Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases". The Journal of Investigative Dermatology 122 (6): 1345–7.  
  • Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H (Feb 1992). "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell 68 (3): 421–7.  
  • Fonatsch C, Latza U, Dürkop H, Rieder H, Stein H (Nov 1992). "Assignment of the human CD30 (Ki-1) gene to 1p36". Genomics 14 (3): 825–6.  
  • Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay". European Journal of Immunology 19 (1): 157–62.  
  • Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl V (Oct 1982). "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". International Journal of Cancer. Journal International Du Cancer 30 (4): 445–59.  
  • Jung W, Krueger S, Renner C, Gause A, Sahin U, Trümper L, Pfreundschuh M (Dec 1994). "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology 31 (17): 1329–34.  
  • Shiota M, Fujimoto J, Semba T, Satoh H, Yamamoto T, Mori S (Jun 1994). "Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3". Oncogene 9 (6): 1567–74.  
  • Lee SY, Park CG, Choi Y (Feb 1996). "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors". The Journal of Experimental Medicine 183 (2): 669–74.  
  • Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB (May 1996). "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". The Journal of Biological Chemistry 271 (22): 12852–8.  
  • Horie R, Ito K, Tatewaki M, Nagai M, Aizawa S, Higashihara M, Ishida T, Inoue J, Takizawa H, Watanabe T (Oct 1996). "A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages". Blood 88 (7): 2422–32.  
  • Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T (Jan 1997). "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation". The Journal of Biological Chemistry 272 (4): 2042–5.  
  • Lee SY, Lee SY, Choi Y (Apr 1997). "TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation". The Journal of Experimental Medicine 185 (7): 1275–85.  
  • Boucher LM, Marengère LE, Lu Y, Thukral S, Mak TW (Apr 1997). "Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily". Biochemical and Biophysical Research Communications 233 (3): 592–600.  
  • Duckett CS, Thompson CB (Nov 1997). "CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes & Development 11 (21): 2810–21.  
  • Mizushima S, Fujita M, Ishida T, Azuma S, Kato K, Hirai M, Otsuka M, Yamamoto T, Inoue J (Jan 1998). "Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)". Gene 207 (2): 135–40.  
  • Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR (Mar 1999). "Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells". Nature 398 (6725): 341–4.  

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.